Stock Track | Intellia Therapeutics Plunges 5.83% in Post-Market on $400 Million Sale Agreement

Stock Track

03/03

Intellia Therapeutics Inc. (NASDAQ: NTLA) saw its shares tumble 5.83% in post-market trading on Monday, following the disclosure of a significant capital raise plan.

The biotech company entered into a sale agreement with Jefferies LLC for the offer and sale of up to $400 million of its common stock, according to an SEC filing. Such equity financing arrangements often lead to investor concerns over potential dilution of existing shareholders' stakes.

The move comes despite positive regulatory news earlier in the day regarding the removal of a clinical hold on a key gene therapy trial. The market's reaction to the financing announcement appears to have overshadowed the earlier development, driving the stock lower after the closing bell.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1182401360"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1182401360\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1182401360?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-03 10:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182401360","market":"hk","top_or_hot":-1,"title":"Stock Track | Intellia Therapeutics Plunges 5.83% in Post-Market on $400 Million Sale Agreement","media":"Stock Track","content":"<p>Intellia Therapeutics Inc. (NASDAQ: NTLA) saw its shares tumble 5.83% in post-market trading on Monday, following the disclosure of a significant capital raise plan.</p><p>The biotech company entered into a sale agreement with Jefferies LLC for the offer and sale of up to $400 million of its common stock, according to an SEC filing. Such equity financing arrangements often lead to investor concerns over potential dilution of existing shareholders' stakes.</p><p>The move comes despite positive regulatory news earlier in the day regarding the removal of a clinical hold on a key gene therapy trial. The market's reaction to the financing announcement appears to have overshadowed the earlier development, driving the stock lower after the closing bell.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Intellia Therapeutics Plunges 5.83% in Post-Market on $400 Million Sale Agreement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Intellia Therapeutics Plunges 5.83% in Post-Market on $400 Million Sale Agreement\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2026-03-03 10:50</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Intellia Therapeutics Inc. (NASDAQ: NTLA) saw its shares tumble 5.83% in post-market trading on Monday, following the disclosure of a significant capital raise plan.</p><p>The biotech company entered into a sale agreement with Jefferies LLC for the offer and sale of up to $400 million of its common stock, according to an SEC filing. Such equity financing arrangements often lead to investor concerns over potential dilution of existing shareholders' stakes.</p><p>The move comes despite positive regulatory news earlier in the day regarding the removal of a clinical hold on a key gene therapy trial. The market's reaction to the financing announcement appears to have overshadowed the earlier development, driving the stock lower after the closing bell.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NTLA","symbol_name":"Intellia Therapeutics Inc","start_time":0,"source_url":"","article_id":"1182401360","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182401360","pubTimestamp":1772506245,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Intellia Therapeutics Inc. (NASDAQ: NTLA) saw its shares tumble 5.83% in post-market trading on Monday, following the disclosure of a significant capital raise plan.The biotech company entered into a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NTLA":"Intellia Therapeutics Inc"},"translate_title":"个股追踪|4亿美元出售协议Intellia Therapeutics盘后暴跌5.83%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTLA":1},"content_text":"Intellia Therapeutics Inc. (NASDAQ: NTLA) saw its shares tumble 5.83% in post-market trading on Monday, following the disclosure of a significant capital raise plan.The biotech company entered into a sale agreement with Jefferies LLC for the offer and sale of up to $400 million of its common stock, according to an SEC filing. Such equity financing arrangements often lead to investor concerns over potential dilution of existing shareholders' stakes.The move comes despite positive regulatory news earlier in the day regarding the removal of a clinical hold on a key gene therapy trial. The market's reaction to the financing announcement appears to have overshadowed the earlier development, driving the stock lower after the closing bell.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}